Michelle M Cloutier, MD, is professor emerita at UCONN Health in Farmington, Connecticut, and chair of the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee Expert Panel Working Group.
These guidelines were developed using extremely high standards, said Michelle M. Cloutier, MD. Cloutier helped update the National Asthma Education and Prevention Program (NAEPP) asthma guidelines.
Transcript
How has the reclassification of asthma as a syndrome with multiple phenotypes impacted diagnosis and treatment advancements?
We’re not quite there in meshing asthma treatment and asthma phenotypes. But the guidelines clearly state that we need to advance this area further. Because currently, we have a step diagram for therapy that's based upon age; it's a one-size-fits-all. But we now know that there isn't one size of asthma, there are these multiple phenotypes. As we move forward, I think we're going to see a separating out [of] the various phenotypes. That is currently being done, to some extent, in the area of the biologics, a whole treatment category for asthma that's not dealt with in the current guidelines, because at the time that the questions were being asked, that the topics were being determined, there was only one biologic on the market. It was felt to be an emerging area and not one that was ready for updating. Clearly, in hindsight, this was a mistake.
Why should providers take these new recommendations into account when treating patients with asthma?
These guidelines were developed using incredibly high standards, using state-of-the-art methodologies for developing guidelines, using strict conflict-of-interest policies. I feel very confident that clinicians should feel comfortable in incorporating these recommendations into their practice. These truly are guidelines that are trustworthy and that are also transparent. All of the recommendations, and all of the information, was developed in a very transparent way. Readers of the guidelines can see the rationale. They may not agree with the recommendation, but they can see how the recommendation was developed and the evidence that was used to support the recommendation.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More